Similar articles

• Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy.

  Wallukat G, Müller J, Hetzer R. Wallukat G, et al. N Engl J Med. 2002 Nov 28;347(22):1806. doi: 10.1056/NEJM200211283472220. N Engl J Med. 2002. PMID: 12456865 No abstract available.
• Are autoantibodies against the beta1-adrenergic receptor markers for dilated cardiomyopathy?

  Arndt-Marić R, Nägele H, Schewe G, Kromminga A. Arndt-Marić R, et al. Clin Lab. 2010;56(11-12):519-26. Clin Lab. 2010. PMID: 21141435
• Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease.

  Levin MJ, Hoebeke J. Levin MJ, et al. Autoimmunity. 2008 Sep;41(6):429-33. doi: 10.1080/08916930802031702. Autoimmunity. 2008. PMID: 18781468 Review.
• Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy.

  Störk S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, Jahns R. Störk S, et al. Am Heart J. 2006 Oct;152(4):697-704. doi: 10.1016/j.ahj.2006.05.004. Am Heart J. 2006. PMID: 16996841
• beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy.

  Jahns R, Boivin V, Lohse MJ. Jahns R, et al. Trends Cardiovasc Med. 2006 Jan;16(1):20-4. doi: 10.1016/j.tcm.2005.11.002. Trends Cardiovasc Med. 2006. PMID: 16387626 Review.